Brief: GT Apeiron Announces Enrollment Of First Patient In Phase 1/2 'Elucidate' Clinical Trial Of Cdk7 Inhibitor, Gtaexs617, In Advanced Solid Tumors

Exscientia

10/07/2023 12:35

July 10 (Reuters) - GT Apeiron:
    * GT APEIRON ANNOUNCES ENROLLMENT OF FIRST PATIENT IN PHASE
1/2
“ELUCIDATE” CLINICAL TRIAL OF CDK7 INHIBITOR, GTAEXS617, IN
ADVANCED SOLID TUMORS
    * GT APEIRON ANNOUNCES ENROLLMENT OF FIRST PATIENT IN PHASE
1/2
“ELUCIDATE” CLINICAL TRIAL OF CDK7 INHIBITOR, GTAEXS617, IN
ADVANCED SOLID TUMORS

Source text for Eikon:  ID:nGNX2XK7sR 

 ((reuters.briefs@thomsonreuters.com;))